Quick Answer
GeneDx Holdings Corp. reported Operating Income Loss of -$13.08 million for the year ending 2025.
- GeneDx Holdings Corp. showed an increase of +43.7% in Operating Income Loss from 2024 to 2025.
- This data is from GeneDx Holdings Corp.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$26.77 million | Q2 2020: -$34.16 million | Q3 2020: -$56.02 million | Q4 2020: -$125.05 million | Q1 2021: -$196.66 million | Q2 2021: -$45.45 million | Q3 2021: -$88.26 million | Q4 2021: -$115.78 million | Q1 2022: -$89.31 million | Q2 2022: -$162.65 million | Q3 2022: -$90.82 million | Q1 2023: -$60.36 million | Q2 2023: -$51.62 million | Q3 2023: -$42.97 million | Q1 2024: -$13.66 million | Q2 2024: -$10.58 million | Q3 2024: -$7.78 million | Q1 2025: -$4.55 million | Q2 2025: $8.96 million | Q3 2025: -$3.25 million.
- Over the full 7 years of available data (2019 to 2025), GeneDx Holdings Corp.'s Operating Income Loss has grown by 57.0%.
- Historical annual values: Fiscal year 2025: -$13.08 million | Fiscal year 2024: -$23.21 million | Fiscal year 2023: -$180.60 million | Fiscal year 2022: -$667.65 million | Fiscal year 2021: -$446.15 million | Fiscal year 2020: -$241.99 million | Fiscal year 2019: -$30.41 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: